University of Oxford’s coronavirus vaccine candidate is the most advanced vaccine candidate against COVID-19 under Phase II trial — which involves thousands of participants in South Africa, UK, and Brazil. Oxford says the potential coronavirus vaccine could be ready by September.
Chinese pharmaceutical, Sinpharm, is the first in the world to start Phase III trials on a potential coronavirus vaccine. The vaccine is being developed in Wuhan — the same place where coronavirus first originated.
The company is working on an “inactivated” vaccine which is produced after scientists are able to grow the virus again in a lab setting and kill it.
Chinese pharmaceutical Sinovac Biotech on July 16 got the approval to conduct Phase III clinical trial for its coronavirus vaccine candidate, CoronaVac. The company will now hire 9,000 health professionals who are currently working in a COVID-19 facility in Brazil and will start the clinical trial this month.
It started developing COVID-19 vaccine as early as January 28. It aims to introduce its coronavirus vaccine this year.
The US-based biotech firm Moderna said on July 14 that it would enter the final stage of human trials for its COVID-19 vaccine on July 27 after the vaccine showed promising results. The Phase 3 trials are likely to have 30,000 volunteers in the US. Half of the participants will be given a 100 mg dose of the vaccine while the other half will receive a placebo. Moderna’s vaccine, if proven successful, could be available by the end of the year or early 2021.
Some of the other institutions whose vaccine candidate which are in the Phase I of the clinical trial include Medicago Inc., Walvax Biotech, Curevac, Imperial College London, University of Queensland, Vaxine Pty Ltd, Clover Biopharmaceuticals, Gamaleya Research Institute, Genexine Consortium and Pfizer.
SEE ALSO:
Wipro share price 16% increase leads to surge in Infosys share price too
Moderna's COVID-19 vaccine will be in final stages of human trial starting July 27
Next Story
